Progenics Pharmaceuticals, Inc, an oncology company, develops, manufactures, and commercializes pharmaceutical products and other technologies to target, diagnose, and treat cancer cancer in the United States and internationally. The company's product candidates include Azedra, a radiotherapeutic product candidate for the treatment of iobenguane scan positive, unresectable, and locally advanced or metastatic pheochromocytoma or paraganglioma for adult and pediatric patients; PyL, a clinical-stage fluorinated prostate specific membrane antigen (PSMA)-targeted PET/CT imaging agent for prostate cancer; and 1095, a PSMA-targeted Iodine-131 labeled small molecule, which is in Phase II clinical trial for the treatment of metastatic castration-resistant prostate cancer.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone646-975-2500
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$15.62 million
Profitability
Miscellaneous
Employees79
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable
Progenics Pharmaceuticals (NASDAQ:PGNX) Frequently Asked Questions
What is Progenics Pharmaceuticals' stock symbol?
Progenics Pharmaceuticals trades on the NASDAQ under the ticker symbol "PGNX."
How were Progenics Pharmaceuticals' earnings last quarter?
Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) posted its earnings results on Friday, August, 9th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.21) by $0.02. The biotechnology company earned $9.97 million during the quarter, compared to the consensus estimate of $6.40 million. Progenics Pharmaceuticals had a negative return on equity of 65.17% and a negative net margin of 339.86%. View Progenics Pharmaceuticals' Earnings History.
When is Progenics Pharmaceuticals' next earnings date?
What price target have analysts set for PGNX?
5 equities research analysts have issued 1-year price objectives for Progenics Pharmaceuticals' shares. Their forecasts range from $6.50 to $14.00. On average, they expect Progenics Pharmaceuticals' share price to reach $10.6250 in the next twelve months. This suggests a possible upside of 200.1% from the stock's current price. View Analyst Price Targets for Progenics Pharmaceuticals.
What is the consensus analysts' recommendation for Progenics Pharmaceuticals?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Progenics Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Progenics Pharmaceuticals.
Has Progenics Pharmaceuticals been receiving favorable news coverage?
Media coverage about PGNX stock has been trending positive on Tuesday, according to InfoTrie Sentiment. The research group identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Progenics Pharmaceuticals earned a media sentiment score of 2.6 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 4.0 out of 10, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the immediate future. View News Stories for Progenics Pharmaceuticals.
Who are some of Progenics Pharmaceuticals' key competitors?
Some companies that are related to Progenics Pharmaceuticals include Phibro Animal Health (PAHC), Epizyme (EPZM), Opko Health (OPK), Theravance Biopharma (TBPH), Athenex (ATNX), Gossamer Bio (GOSS), Innoviva (INVA), ArQule (ARQL), Radius Health (RDUS), Esperion Therapeutics (ESPR), Odonate Therapeutics (ODT), Stoke Therapeutics (STOK), Amphastar Pharmaceuticals (AMPH), Dicerna Pharmaceuticals (DRNA) and Zymeworks (ZYME).
What other stocks do shareholders of Progenics Pharmaceuticals own?
Who are Progenics Pharmaceuticals' key executives?
Progenics Pharmaceuticals' management team includes the folowing people:
- Mr. Mark R. Baker, CEO & Director (Age 64)
- Mr. Patrick Fabbio, Exec. VP & CFO (Age 51)
- Mr. Benedict Osorio, Chief Operating Officer (Age 62)
- Dr. Vivien Wong, Exec. VP of Devel. (Age 62)
- Mr. Bryce V. Tenbarge, Sr. VP of Commercial (Age 46)
Who are Progenics Pharmaceuticals' major shareholders?
Progenics Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (16.22%), Point72 Asset Management L.P. (6.78%), Farallon Capital Management LLC (6.54%), Vanguard Group Inc. (6.45%), Eagle Asset Management Inc. (5.31%) and Rice Hall James & Associates LLC (2.65%). View Institutional Ownership Trends for Progenics Pharmaceuticals.
Which major investors are selling Progenics Pharmaceuticals stock?
PGNX stock was sold by a variety of institutional investors in the last quarter, including Ardsley Advisory Partners LP, Wells Fargo & Company MN, Bank of America Corp DE, Invesco Ltd., Pinnacle Associates Ltd., Phocas Financial Corp., Phocas Financial Corp. and Rice Hall James & Associates LLC. View Insider Buying and Selling for Progenics Pharmaceuticals.
Which major investors are buying Progenics Pharmaceuticals stock?
PGNX stock was acquired by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, Price T Rowe Associates Inc. MD, Nuveen Asset Management LLC, Vanguard Group Inc., BlackRock Inc., Parametric Portfolio Associates LLC, Virtus ETF Advisers LLC and Point72 Asset Management L.P.. View Insider Buying and Selling for Progenics Pharmaceuticals.
How do I buy shares of Progenics Pharmaceuticals?
Shares of PGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Progenics Pharmaceuticals' stock price today?
One share of PGNX stock can currently be purchased for approximately $3.54.
How big of a company is Progenics Pharmaceuticals?
Progenics Pharmaceuticals has a market capitalization of $305.93 million and generates $15.62 million in revenue each year. The biotechnology company earns $-67,660,000.00 in net income (profit) each year or ($0.63) on an earnings per share basis. Progenics Pharmaceuticals employs 79 workers across the globe.View Additional Information About Progenics Pharmaceuticals.
What is Progenics Pharmaceuticals' official website?
How can I contact Progenics Pharmaceuticals?
Progenics Pharmaceuticals' mailing address is ONE WORLD TRADE CENTER 47TH FLOOR, NEW YORK NY, 10007. The biotechnology company can be reached via phone at 646-975-2500 or via email at [email protected]
MarketBeat Community Rating for Progenics Pharmaceuticals (NASDAQ PGNX)
MarketBeat's community ratings are surveys of what our community members think about Progenics Pharmaceuticals and other stocks. Vote "Outperform" if you believe PGNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PGNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
